Found 5 articles
Akouos, a precision genetic medicine company developing gene therapies to restore and preserve hearing, announced today that data from its inner ear gene therapy platform will be presented during the 22nd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), being held April 29 – May 2, 2019 in Washington D.C.
BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* no earlier than 2017.
Arthur Tzianabos, Ph.D. has extensive experience in the development and commercialization of rare disease treatments
Akouos, based in Boston, announced a Series A financing worth $50 million. The round was led by seed investors 5AM Ventures and New Enterprise Associates (NEA).
Lonza, Akouos and MEE Announce Strategic Gene Therapy License Agreements on Hearing and Balance Disorders
The agreement with Akouos is designed to accelerate AAV gene therapy for hearing and balance disorder.